Abstract:Background: Yes-associated protein 1 (YAP1) is the main downstream effector of the Hippo signaling pathway, which is involved in tumorigenesis. This study aimed to comprehensively understand the prognostic performances of YAP1 expression and its potential mechanism in pan-cancers by mining databases. Methods: The YAP1 expression was evaluated by the Oncomine database and GEPIA tool. The clinical significance of YAP1 expression was analyzed by the UALCAN, GEPIA, and DriverDBv3 database. Then, the co-expressed genes with YAP1 were screened by the LinkedOmics, and annotated by the Metascape and DAVID database. Additionally, by the MitoMiner 4.0 v tool, the YAP1 co-expressed genes were screened to obtain the YAP1-associated mitochondrial genes that were further enriched by DAVID and analyzed by MCODE for the hub genes. Results: YAP1 was differentially expressed in human cancers. Higher YAP1 expression was significantly associated with poorer overall survival and disease-free survival in adrenocortical carcinoma (ACC), brain Lower Grade Glioma (LGG), and pancreatic adenocarcinoma (PAAD). The LinkedOmics analysis revealed 923 co-expressed genes with YAP1 in adrenocortical carcinoma, LGG and PAAD. The 923 genes mainly participated in mitochondrial functions including mitochondrial gene expression and mitochondrial respiratory chain complex I assembly. Of the 923 genes, 112 mitochondrial genes were identified by MitoMiner 4.0 v and significantly enriched in oxidative phosphorylation. The MCODE analysis identified three hub genes including CHCHD1, IDH3G and NDUFAF5. Conclusion: Our findings showed that the YAP1 overexpression could be a biomarker for poor prognosis in ACC, LGG and PAAD. Specifically, the YAP1 co-expression genes were mainly involved in the regulation of mitochondrial function especially in oxidative phosphorylation. Thus, our findings provided evidence of the carcinogenesis of YAP1 in human cancers and new insights into the mechanisms underlying the role of YAP1 in mitochondrial dysregulation.

Genome-wide RNA interference screening reveals a COPI-MAP2K3 pathway required for YAP regulation

Yap Promotes The Proliferation Of Neuroblastoma Cells Through Decreasing The Nuclear Location Of P27(Kip1) Mediated By Akt

Inactivation of Yap Oncoprotein by the Hippo Pathway is Involved in Cell Contact Inhibition and Tissue Growth Control

SET1A-Mediated Mono-Methylation at K342 Regulates YAP Activation by Blocking Its Nuclear Export and Promotes Tumorigenesis.

A Coordinated Phosphorylation By Lats And Ck1 Regulates Yap Stability Through Scf Beta-Trcp

TEAD Mediates YAP-dependent Gene Induction and Growth Control

The Role of YAP Transcription Coactivator in Regulating Stem Cell Self-Renewal and Differentiation.

Common and Unique Transcription Signatures of YAP and TAZ in Gastric Cancer Cells

Harness the power: new insights into the inhibition of YAP/Yorkie.

MAML1/2 promote YAP/TAZ nuclear localization and tumorigenesis

Quantitative Real-Time PCR to Measure YAP/TAZ Activity in Human Cells.

Gene Regulation Network of Prognostic Biomarker YAP1 in Human Cancers: An Integrated Bioinformatics Study

Oncogenic YAP mediates changes in chromatin accessibility and activity that drive cell cycle gene expression and cell migration

Negative Regulation Of Yap By Lats1 Underscores Evolutionary Conservation Of The Drosophila Hippo Pathway

Restriction of intestinal stem cell expansion and the regenerative response by YAP

Figure S1 to S13 from YAP is Essential for Treg-Mediated Suppression of Antitumor Immunity

GENE-04. THE ONCOGENIC FUNCTIONS OF YAP1-GENE FUSIONS CAN BE INHIBITED BY DISRUPTION OF YAP1-TEAD INTERACTION

The LKB1–TSSK1B axis controls YAP phosphorylation to regulate the Hippo–YAP pathway

The Dual Functions of YAP-1 to Promote and Inhibit Cell Growth in Human Malignancy.

A non-canonical repressor function of JUN restrains YAP activity and liver cancer growth

Abstract A12: YAP‐dependent induction of amphiregulin identifies a non‐cell‐autonomous component of the Hippo pathway